Integra LifeSciences Expands Uni-CP Compression System Product Range for Mid and Hindfoot Reconstruction

PLAINSBORO, N.J., Jul 16, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will release multiple product line extensions to the Uni-CP(TM) Compression System. The Uni-CP(TM) Compression System has U.S. Food and Drug Administration (FDA) clearance in the United States and a CE Mark Certification in the European Union. Integra will feature the product line extensions at the 25th Annual Summer Meeting of the American Orthopaedic Foot and Ankle Society, July 15-18, 2009, Vancouver, British Columbia, Canada.

"The multiple line extensions for the Uni-CP(TM) Compression System will provide our customers with even greater clinical flexibility when using our highly successful product line," said Pete Ligotti, Vice President, Sales and Marketing, Integra Extremity Reconstruction. "The T-plate offers anatomic metatarsal fixation for demanding procedures such as Lapidus and first metatarsal-cuneiform fusions. The surgeon is also able to choose between staple and plate fixation for Lisfranc procedures."

The Uni-CP(TM) Compression System currently includes a line of compression plates and staples designed for the correction and stabilization of osteotomies and fusions in the foot. Each product employs a diamond shaped bridge design to provide compression through controlled deformation of the implant by the surgeon. The Uni-CP(TM) Compression plates use Surfix(R) locking technology that enables the surgeon to place the plate at the optimal distance from the bone and then lock the screws.

The Uni-CP(TM) product line extensions add the following features and benefits to the Uni-CP(TM) System:

* 2-hole 17mm Interaxis locking plate, designed to accommodate smaller patient anatomy
* 4-hole T-Shape locking plate, designed for increased stability during a Lapidus procedure or 1st metatarsal-cuneiform fusion

Uni-CP(TM) Compression System will be sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Our products are used primarily in neurosurgery, orthopedics and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.Integra-LS.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
Gianna Sabella, Director of Corporate Communications
(609) 936-2389
gsabella@integra-LS.com